APUS vs C · $2.4M cap vs P/E 16, rev $85.22B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
APUS currently screens at market cap $2.4M. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the APUS and C stock pages for the full models.
Not investment advice.